Key result
In 6 of 10 included economic evaluations, dabigatran was a cost-effective alternative to warfarin, with others finding it cost-effective in specific subgroups.
Why the study?
Does dabigatran improve cost-effectiveness compared to warfarin in patients with non-valvular atrial fibrillation?
Systematic Review (n=10)
Does dabigatran improve cost-effectiveness compared to warfarin in patients with non-valvular atrial fibrillation?
Dabigatran is generally a cost-effective alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, particularly in patients with poor INR control or higher stroke risk.
Answers are grounded in this paper and cite their sources.
Supports dabigatran as cost-effective versus warfarin for many non-valvular AF patients; reinforces and extends economic evaluation evidence.
OBJECTIVE: Dabigatran was the first of a new generation of anticoagulation drugs for the indication of non-valvular atrial fibrillation (AF) to be approved. Evidence show that dabigatran 150 mg twice daily significantly reduces the risk of stroke and systemic embolism (RR = 0.65; p < 0.001) and shows a comparable rate of major bleedings (RR = 0.93; p = 0.32), whereas dabigatran 110 mg twice daily was associated with a comparable rate of stroke and systemic embolism (RR = 0.90; p = 0.30) and a significantly lower rate of major bleedings compared to warfarin treatment (RR = 0.80; p = 0.003). The purpose is to review current economic evaluations of these alternatives for healthcare professionals to include these findings in their decision-making. METHODS: A systematic literature search identified 43 economic evaluations, of which 10 were included and evaluated according to the Consensus Health Economic Criteria list (CHEC-list) and the Oxford model. RESULTS: Six economic evaluations concluded that dabigatran was a cost-effective alternative to warfarin. One evaluation concluded the same except when quality in warfarin treatment was excellent, with a mean time in therapeutic range (TTR) > 73%. Three evaluations concluded that dabigatran was a cost-effective alternative to warfarin in patient sub-groups; TTR ≤ 64%, congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke or transient ischemic attack (CHADS2 score) ≥3, or a CHADS2 score = 2 unless international normalized ratio (INR) control was excellent, and with high risk of stroke or in a low-quality warfarin treatment. Dabigatran 110 mg twice daily was in general dominated by dabigatran 150 mg twice daily. LIMITATIONS: The evaluations were not fully homogeneous, as some did not include loss of productivity, costs of dyspepsia, and annual costs of dabigatran patient management. CONCLUSIONS: In the majority of the economic evaluations, dabigatran is a cost-effective alternative to warfarin treatment. In some evaluations dabigatran is only cost-effective in sub-groups, such as patients with a low TTR-value in warfarin treatment and a CHADS2 score ≥2.
No takes yet. Share an insight, caveat, or question.
Hesselbjerg et al. (2013) conducted a systematic review in non-valvular atrial fibrillation (AF) (n=10). Dabigatran vs. Warfarin was evaluated on Cost-effectiveness. In 6 of 10 included economic evaluations, dabigatran was a cost-effective alternative to warfarin, with others finding it cost-effective in specific subgroups.
Synapse has enriched 10 related papers. Consider them for comparative context: